Fisher Asset Management LLC Raises Stock Holdings in Denali Therapeutics Inc. $DNLI

Fisher Asset Management LLC raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 7.6% during the 3rd quarter, Holdings Channel reports. The firm owned 1,631,496 shares of the company’s stock after buying an additional 115,505 shares during the quarter. Fisher Asset Management LLC’s holdings in Denali Therapeutics were worth $23,689,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the second quarter valued at approximately $26,000. State of Wyoming acquired a new stake in Denali Therapeutics during the 2nd quarter valued at approximately $29,000. PNC Financial Services Group Inc. boosted its holdings in shares of Denali Therapeutics by 120.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock valued at $115,000 after acquiring an additional 4,494 shares during the last quarter. Intrust Bank NA acquired a new stake in shares of Denali Therapeutics in the third quarter worth $154,000. Finally, MONECO Advisors LLC raised its holdings in shares of Denali Therapeutics by 19.1% during the third quarter. MONECO Advisors LLC now owns 12,478 shares of the company’s stock worth $181,000 after purchasing an additional 2,000 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on DNLI shares. UBS Group started coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating on the stock. Stifel Nicolaus set a $37.00 price objective on Denali Therapeutics in a report on Monday, November 17th. Wolfe Research began coverage on Denali Therapeutics in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. boosted their price target on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.45.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $20.02 on Wednesday. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -6.74 and a beta of 1.02. The stock has a 50-day moving average of $19.23 and a 200 day moving average of $17.20. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period last year, the business earned ($0.67) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.